
The Trump administration agreed to drop a controversial pilot that would have allowed drugmakers to give post-sales rebates on some drugs instead of upfront discounts.

The Trump administration agreed to drop a controversial pilot that would have allowed drugmakers to give post-sales rebates on some drugs instead of upfront discounts.